- Home
- ACIC vs SAGE Comparison
ACIC vs SAGE Comparison
Compare ACIC & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- SAGE
- Stock Information
- Founded
- ACIC 1999
- SAGE 2010
- Country
- ACIC United States
- SAGE United States
- Employees
- ACIC N/A
- SAGE N/A
- Industry
- ACIC Property-Casualty Insurers
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- SAGE Health Care
- Exchange
- ACIC Nasdaq
- SAGE Nasdaq
- Market Cap
- ACIC 632.9M
- SAGE 462.2M
- IPO Year
- ACIC N/A
- SAGE 2014
- Fundamental
- Price
- ACIC $13.13
- SAGE $5.61
- Analyst Decision
- ACIC Buy
- SAGE Hold
- Analyst Count
- ACIC 1
- SAGE 19
- Target Price
- ACIC $16.00
- SAGE $11.53
- AVG Volume (30 Days)
- ACIC 176.7K
- SAGE 1.1M
- Earning Date
- ACIC 11-06-2024
- SAGE 02-12-2025
- Dividend Yield
- ACIC N/A
- SAGE N/A
- EPS Growth
- ACIC N/A
- SAGE N/A
- EPS
- ACIC 1.76
- SAGE N/A
- Revenue
- ACIC $290,784,000.00
- SAGE $106,399,000.00
- Revenue This Year
- ACIC N/A
- SAGE N/A
- Revenue Next Year
- ACIC $16.25
- SAGE $122.78
- P/E Ratio
- ACIC $7.48
- SAGE N/A
- Revenue Growth
- ACIC 1.02
- SAGE 837.60
- 52 Week Low
- ACIC $8.82
- SAGE $4.62
- 52 Week High
- ACIC $15.08
- SAGE $28.26
- Technical
- Relative Strength Index (RSI)
- ACIC 45.57
- SAGE 50.27
- Support Level
- ACIC $13.73
- SAGE $4.94
- Resistance Level
- ACIC $14.21
- SAGE $5.91
- Average True Range (ATR)
- ACIC 0.62
- SAGE 0.36
- MACD
- ACIC -0.17
- SAGE 0.02
- Stochastic Oscillator
- ACIC 14.47
- SAGE 69.07
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.